PACB - Pacific Biosciences of California, Inc.
| Previous close | 2.56 |
| Open | 2.56 |
| Bid | 2.33 x 2500 |
| Ask | 3.99 x 300 |
| Day's range | 2.52 - 2.62 |
| 52-week range | 2.02 - 5.70 |
| Volume | 371,592 |
| Avg. volume | 970,506 |
| Market cap | 336.274M |
| Beta | 3.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.87 |
| Earnings date | 2 May 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.90 |
- Zacks•12 days ago
Pacific Biosciences Gains as HudsonAlpha Picks Sequel System
Pacific Biosciences (PACB) sees increasing use of Sequel Sequencing System in pediatric and plant biologic case studies.
- Zacks•2 months ago
Pacific Biosciences Unveils New Version of Sequel Software
Pacific Biosciences (PACB) enhances performance and cost-effectiveness of the Sequel System.
- Zacks•2 months ago
Pacific Biosciences (PACB) Down 15.6% Since Earnings Report: Can It Rebound?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•2 months ago
Are Options Traders Betting on a Big Move in Pacific Biosciences (PACB) Stock?
Surging implied volatility makes Pacific Biosciences (PACB) stock lucrative to the option traders.
- Zacks•3 months ago
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
- Motley Fool•3 months ago
What's Behind Pacific Biosciences of California's Sinking Fourth-Quarter Sales
The gene-sequencing company didn't have much good news from the fourth quarter, but better days could be ahead.
- Associated Press•3 months ago
Pacific Biosciences reports 4Q loss
The Menlo Park, California-based company said it had a loss of 18 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Zacks•3 months ago
Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock
Pacific Biosciences (PACB) needs investors to pay close attention to the stock based on moves in the options market lately.
- Motley Fool•3 months ago
Here's Why Pacific Biosciences of California Is Surging Today
Another big purchase order for the genome sequencing equipment manufacturer ahead of its full-year 2017 earnings report is just what investors wanted to see.
- Globe Newswire•3 months ago
BGI Increases Long-Read Sequencing Capacity with Purchase of 10 PacBio Sequel Systems
MENLO PARK, California and SHENZHEN, China, Jan. 25, 2018 (GLOBE NEWSWIRE) -- BGI, one of the world’s largest genomics organizations, and Pacific Biosciences of California, Inc. (Nasdaq: PACB), the leader in long-read sequencing, today announced an agreement by BGI Genomics to purchase an additional 10 Sequel® Systems. This will significantly expand the capacity for Single Molecule, Real-Time (SMRT®) Sequencing for BGI’s global sequencing service business, which currently operates two Sequel Systems and a PacBio® RS II Sequencing System.
- Zacks•3 months ago
What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?
Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.
- Zacks•3 months ago
Pacific Biosciences Hurt by Competition in Niche Markets
Pacific Biosciences (PACB) faces cutthroat competition in the niche space. Also, sluggishness in the European markets is a concern.
- Motley Fool•4 months ago
Better Buy: Illumina, Inc. vs. Pacific Biosciences
One of these vendors of gene sequencing instruments is flexing its muscles and the other is struggling.
- Motley Fool•6 months ago
Why Stamps.com, Pacific Biosciences of California, and Frontier Communications Slumped Today
Get the scoop on why these stocks missed out on Friday's rally.
- Motley Fool•6 months ago
Here's Why Pacific Biosciences of California Is Getting Hammered Today
Despite some bright points, a revenue miss and contracting margins in the company's third-quarter report are taking a toll.
- Motley Fool•6 months ago
Pacific Biosciences of California Posts Big Third Quarter Loss
The genetic-sequencing company's higher system sales aren't enough to offset the loss of contract revenue from Roche.
- Zacks•6 months ago
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
- Associated Press•6 months ago
Pacific Biosciences reports 3Q loss
On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- Zacks•6 months ago
Pacific Biosciences, Bluebee Team Up for De Novo Sequencing
With increasing demand for SMRT sequencing in the genomics community, both Pacific Biosciences (PACB) and partner Bluebee expect a huge customer adoption of integrated de novo assembly pipeline.
